Sugi Predict

Sugi Predict / Compounds / Dibutyl Phthalate

Dibutyl Phthalate

Dibutyl Phthalate

SCHEMBL753014

CCCCOC(=O)c1ccccc1C(=O)OCCCC.Cc1ccccc1C

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 8/20 0.86
▸ TDP1 Q9NUW8 3/20 0.86
▸ L3MBTL1 Q9Y468 2/20 0.86
▸ CYP3A4 P08684 3/20 0.77
▸ MAPK1 P28482 3/20 0.77
▸ TP53 P04637 1/20 0.77
▸ ALDH1A1 P00352 7/20 0.75
▸ LMNA P02545 2/20 0.75
▸ HSD17B10 Q99714 2/20 0.69
▸ KDM4E B2RXH2 2/20 0.60
▸ POLB P06746 1/20 0.60
▸ ESR1 P03372 2/20 0.53
▸ CA2 P00918 1/20 0.53
▸ CYP1A2 P05177 2/20 0.52
▸ CYP2C19 P33261 2/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ CYP2D6 P10635 1/20 0.51
▸ NR1H2 P55055 1/20 0.51
▸ RNASEL Q05823 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
O-Xylene SCHEMBL28032270 0.94 TSHR (0.76) TSHRTDP1L3MBTL1CYP3A4MAPK1
O-Xylene SCHEMBL27364986 0.93 ALDH1A1 (0.87) TSHRTDP1L3MBTL1CYP3A4MAPK1
SCHEMBL6057039 0.93 TSHR (0.80) TSHRTDP1L3MBTL1CYP3A4MAPK1
Dibutyl Phthalate SCHEMBL4596231 0.93 TSHR (1.00) TSHRTDP1L3MBTL1CYP3A4MAPK1
Dibutyl Phthalate SCHEMBL2330224 0.93 TSHR (1.00) TSHRTDP1L3MBTL1CYP3A4MAPK1
Dibutyl Phthalate SCHEMBL29353340 0.93 TSHR (1.00) TSHRTDP1L3MBTL1CYP3A4MAPK1
Dibutyl Phthalate SCHEMBL24051 0.93 TSHR (1.00) TSHRTDP1L3MBTL1CYP3A4MAPK1
Dibutyl Phthalate SCHEMBL30860160 0.91 TSHR (0.89) TSHRTDP1L3MBTL1CYP3A4MAPK1
SCHEMBL888276 0.91 TSHR (0.89) TSHRTDP1L3MBTL1CYP3A4MAPK1
Dibutyl Phthalate SCHEMBL1532115 0.91 TSHR (0.89) TSHRTDP1L3MBTL1CYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3418296-B1 CANCER CELL BINDING RECOMBINANT LECTINS WITH ANTITUMOR ACTIVITY AND METHOD OF PREPARATION UNICHEM LAB LTD (IN) 2024-07-03 — — EP disclosed
CN-109337980-B Application of human YTHDF1 gene 中国科学院昆明动物研究所 2021-11-09 — — CN disclosed
CN-108245686-B The purposes of people's GRK5 gene 中国科学院昆明动物研究所 2019-08-13 — — CN disclosed
CN-107050469-B The purposes of people's NCAPH gene 中国科学院昆明动物研究所 2019-07-30 — — CN disclosed
CN-109498810-A The purposes of AKR1C1 protein inhibitor 中国科学院昆明动物研究所 2019-03-22 — — CN disclosed
CN-109337980-A The purposes of people's YTHDF1 gene 中国科学院昆明动物研究所 2019-02-15 — — CN disclosed
EP-3418296-A1 CANCER CELL BINDING RECOMBINANT LECTINS WITH ANTITUMOR ACTIVITY AND METHOD OF PREPARATION Unichem Laboratories Limited (IN) 2018-12-26 — — EP disclosed
EP-2430041-B1 CANCER CELL BINDING RECOMBINANT LECTINS WITH ANTITUMOR ACTIVITY AND METHOD OF PREPARATION UNICHEM LAB LTD (IN) 2018-10-31 — — EP disclosed
CN-108601525-A Integrated visual morphology and cellular protein expression using resonance light scattering 明策生物医学科技私人有限公司 2018-09-28 — — CN disclosed
CN-108245686-A The purposes of people's GRK5 genes 中国科学院昆明动物研究所 2018-07-06 — — CN disclosed
WO-2013061048-A1 PULMONARY HYPERTENSION UNIVERSITY OF SHEFFIELD (GB) 2013-05-02 — — WO disclosed
US-20130090374-A1 METHODS FOR THE TREATMENT OF TAY-SACHS DISEASE, SANDHOFF DISEASE, AND GM1-GANGLIOSIDOSIS SENA-ESTEVES MIGUEL (US) 2013-04-11 — — US disclosed
WO-2012145646-A1 METHODS FOR THE TREATMENT OF TAY-SACHS DISEASE, SANDHOFF DISEASE, AND GMI-GANGLIOSIDOSIS SENA-ESTEVES MIGUEL (US) 2012-10-26 — — WO disclosed
CN-102388912-A Fosthiazate aqueous emulsion and preparation method thereof GUANGDONG ZHONGXUN AGRICULTURAL TECHOLOGY CO LTD 2012-03-28 — — CN disclosed
EP-2430041-A2 CANCER CELL BINDING RECOMBINANT LECTINS WITH ANTITUMOR ACTIVITY AND METHOD OF PREPARATION Unichem Laboratories Limited (IN) 2012-03-21 — — EP disclosed
EP-1729569-B1 TRANSGENIC MODEL FOR ALZHEIMER'S DISEASE BIOARCTIC NEUROSCIENCE AB (SE) 2011-06-01 — — EP disclosed
WO-2010095143-A2 CANCER CELL BINDING RECOMBINANT LECTINS WITH ANTITUMOR ACTIVITY AND METHOD OF PREPARATION UNICHEM LABORATORIES LTD (IN) 2010-08-26 — — WO disclosed
US-7709695-B1 Transgenic mouse expressing arctic mutation E693G BIOARCTIC NEUROSCIENCE AB (SE) 2010-05-04 — — US disclosed
EP-1729569-A1 TRANSGENIC MODEL FOR ALZHEIMER’S DISEASE Bioarctic Neuroscience AB (SE) 2006-12-13 — — EP disclosed
WO-2005089539-A1 TRANSGENIC MODEL FOR ALZHEIMER’S DISEASE BIOARCTIC NEUROSCIENCE AB (SE) 2005-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090374-A1 METHODS FOR THE TREATMENT OF TAY-SACHS DISEASE, SANDHOFF DISEASE, AND GM1-GANGLIOSIDOSIS GBA1, GAA, GBA2 TSHR 2300/4885TDP1 1034/4885L3MBTL1 758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.